Oncolytic virus immunotherapy induces immunogenic cell death and overcomes STING deficiency in melanoma
Successful immunotherapy for melanoma depends on the recruitment of effector CD8+ T cells to the tumor microenvironment. Factors contributing to T cell regulation in melanoma have recently been recognized, including the stimulator of interferon genes (STING). Agents that can activate STING or enhanc...
Main Authors: | Praveen K. Bommareddy, Andrew Zloza, Samuel D. Rabkin, Howard L. Kaufman |
---|---|
Format: | Article |
Language: | English |
Published: |
Taylor & Francis Group
2019-07-01
|
Series: | OncoImmunology |
Subjects: | |
Online Access: | http://dx.doi.org/10.1080/2162402X.2019.1591875 |
Similar Items
-
Oncolytic HSV: Underpinnings of Tumor Susceptibility
by: Chase Kangas, et al.
Published: (2021-07-01) -
Integrity of the Antiviral STING-mediated DNA Sensing in Tumor Cells Is Required to Sustain the Immunotherapeutic Efficacy of <i>Herpes Simplex</i> Oncolytic Virus
by: Guendalina Froechlich, et al.
Published: (2020-11-01) -
Development of a new fusion-enhanced oncolytic immunotherapy platform based on herpes simplex virus type 1
by: Suzanne Thomas, et al.
Published: (2019-08-01) -
Nectin-1 Expression Correlates with the Susceptibility of Malignant Melanoma to Oncolytic Herpes Simplex Virus In Vitro and In Vivo
by: Barbara Schwertner, et al.
Published: (2021-06-01) -
Triple threat to cancer: rationale for combining oncolytic viruses, MEK inhibitors, and immune checkpoint blockade
by: Praveen K. Bommareddy, et al.
Published: (2019-04-01)